uploads/2018/03/Analysts-Ratings-2-1.png

How Gilead Sciences’ Ranexa, AmBisome, Zydelig, and Vosevi Performed

By

Updated

Ranexa’s revenue trends

In 4Q17, Gilead Sciences’ (GILD) Ranexa generated revenues of $200 million, which reflected a ~5% decline on a year-over-year (or YoY) basis and 22% growth quarter-over-quarter. In fiscal 2017, Ranexa reported revenues of $717 million compared to $677 million in 2016.

Article continues below advertisement

AmBisome revenue trends

In 4Q17, AmBisome generated revenues of $90 million, which is a ~4% decline on a YoY basis and a 2% decline quarter-over-quarter. In 2017, AmBisome reported revenues of $366 million compared to $356 million in 2016.

Zydelig revenue trends

In 4Q17, Zydelig generated revenues of $39 million, which reflected a ~3% decline quarter-over-quarter. In 2017, Zydelig reported revenues of $149 million compared to $168 million in 2016. In the chronic lymphocytic leukemia drugs market, Zydelig competes with Roche and AbbVie’s (ABBV) Venclexta, Johnson & Johnson’s (JNJ) Imbruvica, and Roche’s (RHHBY) Gazyva.

Article continues below advertisement

Vosevi revenue trends

In 4Q17, Vosevi generated revenues of $170 million including revenues of $150 million, $17 million, and $3 million from the US, Europe, and other international markets. In fiscal 2017, Vosevi generated revenues of $293 million, which included revenues of $267 million, $22 million, and $4 million from the US, Europe, and other international markets.

Analyst recommendations

29 analysts were tracking Gilead Sciences in March 2018. Six of them recommended a “strong buy,” while 11 analysts recommended a “buy.” 12 analysts recommended a “hold,” while none of the analysts recommended any form of a “sell.” On March 20, 2018, Gilead Sciences had a consensus 12-month target price of $88.91, which represents a 15.2% return on investment over the next 12 months.

Peer ratings

Of the 23 analysts tracking Bristol-Myers Squibb (BMY) in March 2018, around 39% of analysts recommended some form of a “buy” rating. On March 20, 2018, Bristol-Myers Squib had a consensus 12-month target price of $65.5, which represents a ~0.86% decline over the next 12 months.

Of the 23 analysts tracking AbbVie (ABBV) in March 2018, ~43% of analysts recommended some form of a “buy.” On March 2018, AbbVie had a consensus 12-month target price of $125.9, which represents a ~12.4% return on investment over the next 12 months.

Of the 23 analysts tracking Johnson & Johnson (JNJ) in March 2018, ~52% of analysts recommended some form of a “buy” rating. On March 2018, Johnson & Johnson had a consensus 12-month target price of $150.1, which represents a ~15.3% return on investment over the next 12 months.

Advertisement

More From Market Realist